Personalized Medicines In Oncology Market Research Report: Market size, Industry outlook, Market Forecast, Demand Analysis,Market Share, Market Report 2018-2023
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Personalized Medicines In Oncology Market
Personalized Medicines In Oncology Market: By Tumor (Genomics, Proteomics, Metabolomics) End User (Hospitals, Research Centers, Governmental institutions) Technology (Next-Generation Sequencing, PCR, Others) By Occurrence - Forecast(2018 - 2023)
Report Code : HCR 0097
Updated Date: 31 May, 2018  
5

Copies sold

    Client Rating

1. Market Overview
2. Executive Summary
3. Personalized Medicines In Oncology Landscape

   3.1. Market Share Analysis
   3.2. Comparative Analysis
      3.2.1. Product Benchmarking
      3.2.2. End User Profiling
      3.2.3. Top 5 Financials Analysis
4. Personalized Medicines In Oncology Forces
   4.1. Market Drivers
   4.2. Market Constraints & Challenges
   4.3. Attractiveness of the Personalized Medicines In Oncology Market
      4.3.1. Power of Suppliers
      4.3.2. Threats From New Entrants
      4.3.3. Power of Buyer
      4.3.4. Threat From Substitute Product
      4.3.5. Degree of Competition
5. Personalized Medicines In Oncology -Strategic Analysis
   5.1. Value Chain Analysis
   5.2. Pricing Analysis
   5.3. Opportunity Analysis
   5.4. Product Life Cycle
   5.5. Suppliers and Distributors
6. Personalized Medicines In Oncology- By Tumore Type
   6.1. Genomics
   6.2. Proteomics
   6.3. Metabolomics
   6.4. Epigenetics
7. Personalized Medicines In Oncology- By Service
   7.1. Molecular Oncopathology
   7.2. Genome Diagnostics
   7.3. Radiation Therapy
   7.4. Oncology Testing
   7.5. Chemotherapy
   7.6. Others
8. Personalized Medicines In Oncology- By Occurence
   8.1. Colorectal/ stomach/ esophageal
   8.2. Ovarian
   8.3. Lung
   8.4. Brest
   8.5. Sarcoma
   8.6. Pancreatic
   8.7. Cancer
   8.8. Mesothelioma
   8.9. Others
9. Personalized Medicines In Oncology- By Technology
   9.1. Next-Generation Sequencing
   9.2. Fluorescence/ Chromogenic In Situ Hybridization
   9.3. Immunohistochemistry
   9.4. Microarray
   9.5. Quantitative PCR
   9.6. High Throughput SNP Analysis
   9.7. Others
10. Personalized Medicines In Oncology- By End User
   10.1. Research Centers
   10.2. Governmental Institutions
   10.3. Hospitals
   10.4. others
11. Personalized Medicines In Oncology- Geography
   11.1.  Americas
      11.1.1. U.S.
      11.1.2. Canada
      11.1.3. Brazil
      11.1.4. Others
   11.2. Europe
      11.2.1. U.K.
      11.2.2. Germany
      11.2.3. Italy
      11.2.4. France
      11.2.5. Others
   11.3. Asia Pacific
      11.3.1. China 
      11.3.2. Japan
      11.3.3. Australia & New Zealand
      11.3.4. Others
   11.4. Rest of The World (RoW)
      11.4.1. Middle East
      11.4.2. Africa
12. Personalized Medicines In Oncology Entropy
   12.1. New Product Developments
   12.2. Product Launches, JVs, Mergers and Acquisitions
13. Company Profiles
   13.1. Agendia Nv
   13.2. Allere Laboratory
   13.3. Alpha Genomix
   13.4. Ariana Pharma
   13.5. Biocrates
   13.6. Biodiscovery
   13.7. Biotheranostics
   13.8. Boreal Genomics, Inc.
   13.9. Caris Life Sciences
   13.10. Chordoma Foundation
   13.11. CompanionDx
   13.12. Cypher Genomics
   13.13. deCode Genetics
   13.14. Diploid
   13.15. DNA Link
   13.16. Edge Bio
   13.17. Foundation Medicine
   13.18. Fulgent Diagnostics
   13.19. Gene TLC
   13.20. GenebyGene
   13.21. Genomic Engenharia Molecular
   13.22. Genomic Health, Inc.
   13.23. Illumina, Inc. 
   13.24. Life Technologies Corporation
   13.25. MapMyGenome
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
14. Appendix

   14.1. Abbreviations
   14.2. Sources
   14.3. Research Methodology
   14.4. Bibliography
   14.5. Compilation of Expert Insights
Please select Licence
Single User Licence:
US $5250
Corporate User Licence:
US $7250
Related Reports
0px;">Scroll